Table 8.
Control Condition | Pre-Treatment Period | Treatment Period | Post-Treatment Period | |||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
M1 | M2 | M3 | M4 | M5 | M6 | M7 | M8 | M9 | M10 | M11 | M12 | |
All Subjects | 6.01 | 6.11 | 6.13 | 6.13 | 6.20 | 6.15 | 6.01 | 6.01 | 6.00 | 6.08 | 5.86 | 6.20 |
(n = 19) | (0.11) | (0.09) | (0.08) | (0.10) | (0.11) | (0.06) | (0.07) | (0.07) | (0.08) | (0.09) | (0.08) | 0.08) |
Low PA (n = 9) |
5.95 (0.21) |
5.93 (0.11) |
6.00 (0.14) |
6.07 (0.16) |
6.12 (0.17) |
6.11 (0.09) |
5.86 (0.07) |
5.86 (0.07) |
5.91 (0.11) |
6.02 (0.14) |
5.99 (0.12) |
6.11 (0.12) |
High PA (n = 10) |
6.05 (0.11) |
6.20 (0.10) |
6.24 (0.10) |
6.19 (0.13) |
6.36 (0.12) |
6.19 (0.09) |
6.14 (0.12) |
6.14 (0.12) |
6.05 (0.12) |
6.14 (0.12) |
6.02 (0.08) |
6.28 (0.11) |
Low SRWC (n = 9) |
6.21 (0.18) |
6.28 (0.13) |
6.17 (0.17) |
6.13 (0.15) |
6.17 (0.13) |
6.29 (0.14) |
5.85 (0.14) |
5.85 (0.14) |
5.99 (0.12) |
6.25 (0.12) |
6.16 (0.16) |
6.37 (0.14) |
High SRWC (n = 10) |
6.30 (0.18) |
6.15 (0.10) |
6.14 (0.09) |
6.18 (0.14) |
6.31 (0.15) |
6.18 (0.14) |
6.25 (0.15) |
6.25 (0.15) |
6.19 (0.13) |
6.15 (0.11) |
5.94 (0.13) |
6.10 (0.11) |
Low PRAL (n = 9) |
6.06 (0.22) |
6.11 (0.16) |
6.22 (0.15) |
6.22 (0.17) |
6.23 (0.17) |
6.23 (0.11) |
5.92 (0.11) |
5.92 (0.11) |
5.92 (0.13) |
5.98 (0.16) |
5.87 (0.15) |
6.16 (0.14) |
High PRAL (n = 10) |
5.96 (0.10) |
6.11 (0.09) |
6.04 (0.09) |
6.06 (0.11) |
6.36 (0.36) |
6.08 (0.07) |
6.08 (0.10) |
6.08 (0.10) |
6.04 (0.10) |
6.18 (0.08) |
5.86 (0.09) |
6.24 (0.09) |
Note: There were a total of twelve 24-hour urine collections labeled in the table as M1-M12, respectively. Mean pH values were compared directly with respective mean Pre-Treatment reference value which were averages of all M1-M3 values within the condition and subject group being evaluated. These Pre-Treatment reference values were as follows: 6.08 (all Control subjects), 5.96 (low PA), 6.16 (high PA), 6.22 (low SRWC), 6.20 (high SRWC), 6.13 (low PRAL), and 6.04 (high PRAL).